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Abstract
Genome-wide association studies (GWAS) have identified ,100 loci associated with blood lipid levels, but much of the trait
heritability remains unexplained, and at most loci the identities of the trait-influencing variants remain unknown. We
conducted a trans-ethnic fine-mapping study at 18, 22, and 18 GWAS loci on the Metabochip for their association with
triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), respectively,
in individuals of African American (n = 6,832), East Asian (n = 9,449), and European (n = 10,829) ancestry. We aimed to
identify the variants with strongest association at each locus, identify additional and population-specific signals, refine
association signals, and assess the relative significance of previously described functional variants. Among the 58 loci, 33
exhibited evidence of association at P,161024 in at least one ancestry group. Sequential conditional analyses revealed that
ten, nine, and four loci in African Americans, Europeans, and East Asians, respectively, exhibited two or more signals. At
these loci, accounting for all signals led to a 1.3- to 1.8-fold increase in the explained phenotypic variance compared to the
strongest signals. Distinct signals across ancestry groups were identified at PCSK9 and APOA5. Trans-ethnic analyses
narrowed the signals to smaller sets of variants at GCKR, PPP1R3B, ABO, LCAT, and ABCA1. Of 27 variants reported previously
to have functional effects, 74% exhibited the strongest association at the respective signal. In conclusion, trans-ethnic high-
density genotyping and analysis confirm the presence of allelic heterogeneity, allow the identification of population-specific
variants, and limit the number of candidate SNPs for functional studies.
Citation: Wu Y, Waite LL, Jackson AU, Sheu WH-H, Buyske S, et al. (2013) Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic
Heterogeneity That Increases the Trait Variance Explained. PLoS Genet 9(3): e1003379. doi:10.1371/journal.pgen.1003379
Editor: Greg Gibson, Georgia Institute of Technology, United States of America
Received August 1, 2012; Accepted January 19, 2013; Published March 21, 2013
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The data and materials included in this report result from a collaboration among the following studies. PAGE: The Population Architecture Using
Genomics and Epidemiology (PAGE) program is funded by the National Human Genome Research Institute (NHGRI), supported by U01HG004803 (CALiCo),
U01HG004798 (EAGLE), U01HG004802 (MEC), U01HG004790 (WHI), and U01HG004801 (Coordinating Center), and their respective NHGRI ARRA supplements. The
contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Funding support for the Genetic
Epidemiology of Causal Variants Across the Life Course (CALiCo) program was provided through the NHGRI PAGE program (U01HG004803 and its NHGRI ARRA
supplement). The Atherosclerosis Risk in Communities (ARIC) Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute
contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The Multiethnic Cohort study (MEC)
characterization of epidemiological architecture is funded through the NHGRI PAGE program (U01HG004802 and its NHGRI ARRA supplement). The MEC study is
funded through the National Cancer Institute (R37CA54281, R01 CA63, P01CA33619, U01CA136792, and U01CA98758). Funding support for the ‘‘Epidemiology of
putative genetic variants: The Women’s Health Initiative’’ study is provided through the NHGRI PAGE program (U01HG004790 and its NHGRI ARRA supplement).
The WHI program is funded by the National Heart, Lung, and Blood Institute; NIH; and U.S. Department of Health and Human Services through contracts
N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. Assistance with phenotype
harmonization, SNP selection and annotation, data cleaning, data management, integration and dissemination, and general study coordination was provided by
the PAGE Coordinating Center (U01HG004801-01 and its NHGRI ARRA supplement). The National Institutes of Mental Health also contributes to the support for
the Coordinating Center. HyperGEN: The hypertension network is funded by cooperative agreements (U10) with NHLBI: HL54471, HL54472, HL54473, HL54495,
HL54496, HL54497, HL54509, HL54515, and 2 R01 HL55673-12. CLHNS: The Cebu Longitudinal Health and Nutrition Survey (CLHNS) was supported by National
Institutes of Health grants DK078150, TW05596, and HL085144 and pilot funds from RR20649, ES10126, and DK56350. TAICHI: The TAICHI Metabochip study was
supported by NHLBI grant HL087647. Financial support for HALST was through grants from the National Health Research Institutes (PH-100-SP-01). The SAPPHIRe
was supported by grants from the National Health Research Institutes (BS-094-PP-01 and PH-100-PP-03). The TCAGEN was partially supported by grants NTUH.98-
N1266, NTUH100-N1775, NTUH101-N2010, NTUH101-N, VN101-04, and NTUH 101-S1784 from National Taiwan University Hospital, NSC 96-2314-B-002-152, and
NSC 101-2325-002-078. The TACT was supported by grants from the National Science Council of Taiwan (NSC96-2314-B-002-151, NSC98-2314-B-002-122-MY2, and
NSC 100-2314-B-002-115). The Taiwan Dragon and TACD were supported by grants from the National Science Council (NSC 98-2314-B-075A-002-MY3) and
Taichung Veterans General Hospital, Taichung, Taiwan (TCVGH-1013001C; TCVGH-1013002D). FUSION 2: Support for FUSION was provided by NIH grants
DK062370, DK072193, and intramural project number 1Z01-HG000024. FIN-D2D2007: The FIN-D2D study has been financially supported by the hospital districts
of Pirkanmaa, South Ostrobothnia, and Central Finland; the Finnish National Public Health Institute (current National Institute for Health and Welfare); the Finnish
Diabetes Association; the Ministry of Social Affairs and Health in Finland; the Academy of Finland (grant number 129293); the Commission of the European
Communities; Directorate C-Public Health (grant agreement no. 2004310); and Finland’s Slottery Machine Association. DPS: The Finnish Diabetes Prevention
Study (DPS) has been financially supported by grants from the Academy of Finland (117844 and 40758, 211497, and 118590), the EVO funding of the Kuopio
University Hospital from Ministry of Health and Social Affairs (5254), Finnish Funding Agency for Technology and Innovation (40058/07), Nordic Centre of
Excellence on Systems Biology in Controlled Dietary Interventions and Cohort Studies, SYSDIET (070014), The Finnish Diabetes Research Foundation, Yrjö
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Introduction
Genome-wide association studies (GWAS) have identified many
common genetic variants associated with human diseases and
complex traits (www.genome.gov/gwastudies), including ,100
loci associated with triglycerides (TG), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
or total cholesterol [1–5]. A majority of the lead SNPs at these loci
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have shown small effect sizes, leaving much of the trait heritability
unexplained. Some of this missing heritability may be due to the
incomplete coverage of functional common or rare variants and
the poor representation of appropriate proxies on commercial
genotyping arrays [6,7]. Other missing heritability may result from
a failure to detect the full spectrum of causative variants present at
GWAS-identified loci.
Fine-mapping of GWAS signals should increase the power to
detect variants that influence trait variability. Genotyping of
additional variants at GWAS loci can identify SNPs with stronger
evidence of association than the reported GWAS index SNPs and
may help detect or further localize the underlying causal variants
[7,8]. The Metabochip is a high-density custom genotyping array
designed to replicate and fine-map known GWAS signals for
metabolic and atherosclerotic/cardiovascular endpoints, and more
extensively, to identify all signals around the index SNPs [9,10].
The fine-mapping SNPs spanned a wide range of allele frequencies
including rare (minor allele frequency (MAF),0.005) and less
common (0.005#MAF,0.05) SNPs selected from the catalogs of
the International HapMap Project and the August 2009 release of
the 1000 Genomes Project. SNPs annotated as nonsynonymous,
essential splice site or stop codon were included regardless of
MAF, design score, or the presence of nearby SNPs [10]. The
Metabochip contains densely spaced SNPs at 18, 22, and 18 loci
previously reported for TG, HDL-C, and LDL-C, respectively.
Allelic heterogeneity, in which different variants at the same
gene/locus affect the same phenotype, is a frequent characteristic
of both single-gene and complex disorders. Recently GWAS have
identified more than one independent signal at loci associated with
coronary artery disease [11] and type 2 diabetes [12,13]. Among a
set of 30 lipid loci reported through GWAS, secondary SNPs that
exhibited weak to moderate LD with the corresponding index
SNPs and displayed little change of association in conditional
analyses were detected at seven loci including CETP, LIPC,
APOA5, APOE, LDLR, ABCG8, and LPL [4]. More than one
association signal also was detected at 26 of 95 lipid loci reported
by the Global Lipids Genetics Consortium [5]. However, allelic
heterogeneity has not been comprehensively evaluated for
common traits including lipid traits across ethnically diverse
populations, especially in non-European populations such as
African Americans and East Asians.
Due to divergent evolutionary and migratory histories, patterns
of linkage disequilibrium (LD) vary across ancestry groups [14].
Greater haplotype diversity in some ancestry groups, especially in
African ancestry populations, may facilitate the localization of
functional variants that show association signals delimited in part
due to weaker LD with neighboring SNPs [14,15]. A recent multi-
ethnic analysis of lipid associated loci demonstrated that genetic
determinants at many lipid loci differed between European
Americans and African Americans [16]. For example, in African
Americans from the PAGE consortium [9,17], a reported
regulatory variant rs12740374 at CELSR2/PSRC1/SORT1 locus
[18] was more strongly associated with LDL-C compared to many
nearby variants demonstrating similar strength of association in
European ancestry individuals [5]. High-density genotyping
enables trans-ethnic fine-mapping studies to narrow the set of
plausible candidate functional variants at GWAS loci without
introducing uncertainty through imputation [19].
In this study, we analyzed high-density genotyped SNPs on the
Metabochip for their associations with TG, HDL-C, and LDL-C
in 6,832 African Americans, 9,449 East Asians, and 10,829
Europeans at 58 known lipid loci. We sought to (i) identify the
variants with the strongest evidence of association at each locus in
populations with different ancestries and in the combined trans-
ethnic samples; (ii) investigate allelic heterogeneity and population-
specific signals at the established lipid loci; (iii) explore whether
high-density genotyping in diverse ethnic populations would
narrow the sets of plausible candidate functional variants for
further study; and (iv) assess whether the variants reported to have
functional effects on gene expression or protein function during
the past 30 years of biological study exhibited the strongest
evidence of association at the corresponding GWAS signals.
Results
Loci with evidence of association in diverse populations
and in the combined trans-ethnic samples
Descriptions of the collection, phenotyping, and genotyping of
study samples for each study site are provided in Table S1. Given
that all 58 loci have a priori genome-wide significant evidence of
association with one or more of these three lipid traits, we used a P
value threshold of 161024 as an approximate correction for the
mean of 451 SNPs tested at each locus in African Americans
(Table S2). An average of 273 SNPs per locus was tested in East
Asians and an average of 291 in Europeans, but we applied the
same, more conservative, P value threshold of 161024 to these two
groups as well.
A total of 33 loci (nine for TG, 14 for HDL-C, and 10 for LDL-
C) exhibited evidence of association at P,161024 in at least one
of the three ancestry groups, including 22 loci in African
Americans, 17 in East Asians, and 31 in Europeans (Table S3A–
S3C). The variants that reached this threshold of significance were
common (MAF$0.05), except at three loci (PCSK9 and ABO for
LDL-C, and APOA5 for HDL-C) in African Americans and two
loci (PCSK9 and TOP1, both for LDL-C) in European ancestry
individuals. When individuals of diverse ancestry groups were
combined, 11, 15, and 12 loci showed evidence of significant
association with TG, HDL-C, and LDL-C, respectively (Table
S4A–S4C). Among these 38 loci, six loci had not reached the P
value threshold of 1024 within any individual ancestry group,
including CETP and NAT for TG, GALNT2 and MMAB for HDL-
C, and TRIB1 and TIMD4 for LDL-C. One locus, COBLL1, was
Author Summary
Lipid traits are heritable, but many of the DNA variants that
influence lipid levels remain unknown. In a genomic region,
more than one variant may affect gene expression or
function, and the frequencies of these variants can differ
across populations. Genotyping densely spaced variants in
individuals with different ancestries may increase the
chance of identifying variants that affect gene expression
or function. We analyzed high-density genotyped variants
for association with TG, HDL-C, and LDL-C in African
Americans, East Asians, and Europeans. At several genomic
regions, we provide evidence that two or more variants can
influence lipid traits; across loci, these additional signals
increase the proportion of trait variation that can be
explained by genes. At some association signals shared
across populations, combining data from individuals of
different ancestries narrowed the set of likely functional
variants. At PCSK9 and APOA5, the data suggest that
different variants influence trait levels in different popula-
tions. Variants previously reported to alter gene expression
or function frequently exhibited the strongest association at
those signals. The multiple signals and population-specific
characteristics of the loci described here may be shared by
genetic loci for other complex traits.
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significantly associated with HDL-C in Europeans alone
(P = 8.561025), but displayed less evidence of association in the
combined trans-ethnic samples (P = 1.661024).
Loci with evidence of multiple signals at a locus, and
often population-specific signals
To assess the presence of two or more signals at each locus that
exhibited evidence of association in at least one ancestry group, we
performed sequential conditional analyses by adding the most
strongly associated SNP to the regression model as a covariate and
testing the association with each of the remaining regional SNPs
independently. A set of sequential conditional analyses were
followed by inclusion of the strongest SNP in each conditional
model until the most strongly associated SNP showed a
conditional P value.1024 and was not annotated as a nonsense
or nonsynonymous substitution. We also investigated whether
association signals were population-specific, which we defined as
association signals with variants that are not variable in the
samples from the other two ancestry groups in this study or in the
1000 Genomes Project populations that represent those groups
among total European ancestry (EUR), total East Asian ancestry
(ASN), or total west African ancestry (AFR).
In African Americans, sequential conditional analyses revealed
that 10 of the 22 loci with evidence of association exhibited two or
more signals at P,1024 (Table 1). Two loci (PCSK9 and the
TOMM40-APOE-APOC4 cluster; both for LDL-C) each had seven
signals, four loci (APOB for LDL-C, LDLR for LDL-C, LCAT for
HDL-C, and CETP for HDL-C) had three signals, and another
four loci (APOB, APOC1, APOA5, and LPL; all for TG) had two
signals. Among the 10 loci with two or more signals, all these
signals led to an average 1.8-fold increase in the amount of
phenotypic variance (R2) compared to that explained by the
strongest signals alone (See Method) in African Americans. Among
these 34 signals, 15 were represented by less common
(0.005#MAF,0.05, n = 11) or rare (MAF,0.005, n = 4) variants.
In addition, 15 signals at eight loci were African American-
specific. If we only include SNPs that meet a locus-specific P-value
threshold based on the number of genotyped SNPs (Table S2),
LPL for TG and APOB for both TG and LDL each had one signal,
and the seven loci with multiple signals still showed an average of
1.8-fold increase in the explained phenotypic variance.
The seven signals at PCSK9 in African Americans included six
nonsense or nonsynonymous variants previously shown to
associate with LDL-C levels and to affect PCSK9 expression or
function [20–22], along with an unreported intronic variant
(Table 1). The strongest signals were a nonsense variant
rs28362286 (C679X, Figure 1A) and a nonsynonymous variant
rs28362263 (A443T, Figure 1B), which showed no reduction of
association evidence when conditioned on C679X. Conditional
analysis on both C679X and A443T yielded a third signal at
rs28362261 (N425S, Figure 1C); and further conditional analyses
successively implicated rs67608943 (Y142X, Figure 1D),
rs72646508 (L253F, Figure 1E), and an intronic variant
rs11800243 (Figure 1F). The seventh signal, which did not reach
the Pconditional,10
24 threshold, was represented by the nonsynon-
ymous variant rs11591147 (R46L, Figure 1G) that exhibited the
strongest and directionally consistent evidence of association with
LDL-C in Europeans (Pinitial = 2.8610
230, Table 2). The seven
signals were weakly correlated with each other in African
American individuals, and all pairwise LD r2 values were less
than 0.02. Among the seven PCSK9 signals, the top five were
African American-specific, and six were either less common or
rare in African Americans. The lead SNP C679X accounted for
1.3% of the explained LDL-C phenotypic variance and the seven
signals together explained 3.6% of the phenotypic variance in
African Americans. PCSK9 exhibited two signals in Europeans
(R46L and rs2495477, Table 2), but no SNP reached Pinitial,10
24
in East Asians.
At the TOMM40-APOE-APOC4 cluster, the seven signals in
African Americans explained 6.6% of the LDL-C phenotypic
variance compared to 4.1% explained by the strongest signal
R176C, which had reported functional effects [23] (Table 1, Figure
S1). These seven signals were not entirely independent of one
another. The fourth signal, rs157588, showed association with
LDL-C (P = 2.061027) only after conditioning on the top three
signals, but not in the original unconditioned association analysis
(P = 0.72). The trait-decreasing allele (G allele: freq = 0.176) of
rs157588 was present on haplotypes containing the trait-increasing
allele of the third signal rs1038026 (A allele: freq = 0.351), thus the
association of the fourth signal increased in significance after
accounting for linkage disequilibrium (r2/D9 = 0.35/0.92) with the
third signal at the same locus. Haplotype analysis revealed that
compared to the reference A-A (increasing-increasing) haplotype,
the G-G (decreasing-decreasing) haplotype only displayed modest
association with LDL-C (P = 7.561023), but the A–G (rs1038026
increasing- rs157588 decreasing) haplotype showed significant
association with decreased level of LDL-C (P = 1.5610210) (Table
S5). In Europeans (Table 2) and East Asians (Table 3), three and two
signals were identified at TOMM40-APOE-APOC4, respectively.
The known functional variant R176C exhibited the strongest
evidence of association across the three ancestry groups, with effect
sizes of 20.536, 20.505, and 20.411 mmol/L in individuals of
African American, European, and East Asian ancestry, respectively
(Table 1). However, another APOE variant rs429358 (C130R), that
together with R176C, defines the three major isoforms of APOE (e2,
e3, and e4) [7,24], was not successfully genotyped, therefore the
LDL-C association with either C130R or the APOE haplotype was
unavailable in this study.
In Europeans, 21 signals at nine of the 31 loci exhibited multiple
signals for at least one of the three lipid traits at P,1024 (Table 2).
Three loci (APOA5 for TG, TOMM40-APOE-APOC4 cluster for
LDL-C, and CETP for HDL-C) each had three signals while
another six loci (PCSK9 for LDL-C, GCKR for TG, LIPC for HDL-
C, APOB for LDL-C, and LPL for both TG and HDL-C) each had
two signals. At the nine loci that had two or more signals, all
association signals resulted in an average of 1.3-fold increase in the
explained phenotypic variance compared to the strongest signals
alone across loci. At PCSK9, rs11591147 (R46L) exhibited the
strongest evidence of association in Europeans. As reported above,
R46L also represented the seventh signal in African Americans.
R46L accounted for 1.2% of the total variation in LDL-C levels in
Europeans compared the 0.16% in African Americans. This SNP
was not variable in the 1000 Genomes Project ASN samples (East
Asian ancestry) and the .9,000 East Asian individuals in this
study.
In East Asians, we observed three signals at the TG locus
APOA5, and two signals at three loci including TOMM40-APOE-
APOC4 cluster for LDL-C, CETP for HDL-C, and ABO for LDL-
C (Table 3). At the four loci that exhibited multiple signals, all the
association signals increased the explained phenotypic variance by
an average of 1.3-fold compared to the strongest signal across loci.
The second signal at APOA5 was the nonsynonymous variant
G185C previously reported to affect the protein function [25].
Although G185C was not unique to East Asians, the frequency
was very low in African Americans (MAF = 0.002, P = 0.028) and
Europeans (MAF = 0.0003, P = 0.23), and the low allele frequency
meant that this study had less than 5% statistical power to detect
the association in these groups.
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At APOA5, which exhibited multiple signals in all three
populations (Table 1, Table 2, Table 3), the strongest TG-
associated SNPs differed and were not in high LD (r2,0.8) with
each other in any of the ancestry groups. In African Americans,
the two signals S19W (MAF = 0.058, P = 8.4610215) and
rs79624460 (MAF = 0.083, P = 4.8610212), showed no evidence
of significant association in East Asians (Table 1), likely due to the
low allele frequency and the limited power (,10%) to detect the
association. The three signals at APOA5 in East Asians were only
modestly associated with TG in African Americans (all P.1023,
Table 3). The SNP LD r2 values between the African American
and East Asian signals were less than 0.02 in both populations,
suggesting that they represent distinct APOA5 signals in the two
ancestry groups. In addition, the APOA5 signal rs3741298
(P = 9.7610244, MAF = 0.222) in Europeans exhibited evidence
of association with TG in African Americans (P = 9.861025,
MAF = 0.327) and East Asians (P = 1.2610220, MAF = 0.357), but
the significance levels of the association with rs3741298 were
substantially attenuated by conditioning on the strongest signals
S19W in African Americans (P = 0.10) and rs651821 in East
Asians (P = 0.88). In Europeans, the associations with rs3741298
were partially removed when conditioning on S19W and rs651821
(Pconditional = 1.7610
228 and 3.1610217, respectively). The Europe-
an signal rs3741298 was moderately correlated with the African
American signal S19W (LD r2 = 0.21 and 0.10 in the 1000
Genomes Project EUR samples (European ancestry) and in PAGE
African American samples, respectively), and with the East Asian
signal rs651821 (LD r2 = 0.31 and 0.28 in 1000 Genomes Project
EUR and ASN samples, respectively). Notably, the effect sizes of
the two reported functional variants S19W [26] and G185C [25]
at APOA5 were similar across the three groups (S19W, African
American: 0.136; East Asian: 0.136; European: 0.121 and G185C,
African American: 0.204; East Asian: 0.201; European:
0.269 mmol/L in loge scale) despite the limited power to detect
significant evidence of association at low allele frequencies. These
findings support the hypothesis that causative variants may have a
similar genetic impact on trait variation across populations if not
influenced by hidden gene-gene or gene-environment interactions
[27]. We also observed that the second European signal
rs75919952 exhibited nominal evidence of association (P
initial = 0.018, MAF = 0.041), but was not associated with TG in
the other two groups (Table 2). The lack of association may be due
to insufficient power (15% and 55% in African Americans and
East Asians, respectively; assuming a= 0.05) corresponding to the
lower allele frequency (MAF = 0.012) in African Americans, the
smaller sample sizes in both populations, or underlying interac-
tions.
Trans-ethnic high-density genotyping narrowed the
region of association signals
We next examined whether trans-ethnic meta-analysis or
comparison across ancestries would refine the association signals
by narrowing the genomic regions where functional variants might
be expected to reside. The trans-ethnic analysis allowed the
refinement of association signals at loci of GCKR, PPP1R3B, ABO,
LCAT, and ABCA1 (Table 4, Table S3A–S3C). The signal at
GCKR was localized to the reported functional variant P446L [28]
due to the limited LD in African Americans (Figure S2A–S2D).
Notably, there were seven and six variants in high LD (r2.0.8)
with P446L in the 1000 Genomes Project ASN and EUR samples,
but no SNP with LD r2.0.8 in African American individuals. At
the signal ,200 kb from the PPP1R3B gene for which no
functional regulatory variant(s) have been reported, the association
signal was narrowed from 4 SNPs spanning 36 kb (P,1024) in
Europeans to two highly correlated SNPs located 1 kb apart in
African Americans (rs6601299, P = 8.061028 and rs4841132,
P = 2.961027; LD r2.0.94) (Figure 2). The lead SNP rs6601299
was in high LD with 11 variants in the 1000 Genomes Project
EUR samples but only highly correlated with two and one variant
in the 1000 Genomes Project AFR samples (West African
ancestry) and PAGE African American individuals, respectively.
At the ABO locus, trans-ethnic meta-analysis revealed six SNPs
exhibiting stronger evidence of association (P,1.1610211) with
LDL-C compared to other variants in the same region
(P.2.361027) (Figure S3A–S3D). At the locus LCAT for HDL-
C, the association signals spanned ,800 kb, ,360 kb, and
,360 kb in Europeans, East Asians, and African Americans, with
a ,50 kb overlapping region. Trans-ethnic meta-analysis of all
samples localized the signal to four variants spanning this 50 kb
region (Figure S4A–S4D). At HDL-C locus ABCA1, the reported
GWAS index SNP rs1883025 consistently showed the strongest
association within each of the three ancestry groups that we
examined, but the significance level of the association was similar
to those of the nearby SNPs. Trans-ethnic meta-analysis refined
the signal by revealing that rs1883025 (P = 4.3610217) and
rs2575876 (P = 1.8610215) displayed much stronger association
than the neighboring SNPs (P.8.4610210) (Figure S5A–S5D).
Reported functional variants were frequently the most
strongly associated ones at a signal
Among loci associated with at least one lipid trait (P,1024), at
least 27 variants at 15 loci have been previously reported
[18,22,23,25,26,28–47] to functionally influence gene expression
or protein function in vitro (Table 5). Among the 27 variants, 17 are
present on the Metabochip and two are well-represented by
perfect proxies in complete LD (r2 = 1) based on the 1000
Genomes Project EUR data. Of the 19 reported functional
variants, 14 (74%) exhibited the strongest association P-value
among all SNPs at that signal in at least one population. In
addition, two more reported functional variants (APOB-rs7575840,
P = 7.0610217 and LPL-rs328, P = 2.3610211) were in high LD
(r2.0.95) with the most strongly associated variants and showed
similar evidence of association (APOB-rs934198, P = 3.7610217;
LPL-rs1803924, P = 1.1610211). If we include these two variants,
then 16 of the 19 (84%) reported functional variants displayed the
strongest association P-value at the primary, secondary, or
successive signals. The remaining three reported functional
variants: LDLR-rs688 (N591N), LPL-rs1801177 (D9N), and
HMGCR-rs3761740 (911C.A), were poorly tagged (LD r2,0.2)
by the strongest variants in our data. Additional functional
variants may exist at these loci that have not yet been reported to
change gene expression/protein function or that were not
identified in our literature search. For example, P2739L and
P145S that represented the two signals at APOB (Table 1) were
predicted by PolyPhen [48] to be ‘probably damaging’ with a
score of ‘1’, although their functional roles were unclear.
Figure 1. LDL-C locus PCSK9 exhibited seven signals in African Americans. Initial association in the main analysis (A). Residual association in
sequential conditional analysis by sequentially adding the lead SNPs into the regression model (B–G). Each SNP was colored according to its LD (r2) in
the PAGE consortium, with the strongest SNP colored in purple and symbols designating genomic annotation defined in the ‘annotation key’.
Genomic coordinates refer to build 36 (hg18).
doi:10.1371/journal.pgen.1003379.g001
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Among the 16 reported functional variants and proxies that
exhibited the strongest association P-value at a signal (Table 5),
R176C at APOE was strongest in all three populations and GCKR
L446P was identified in both African Americans and Europeans.
The remaining 14 variants showed the strongest associations in
only one of the populations, including 10 in African Americans,
three in East Asians, and one in Europeans. Five of the 10 variants
in African Americans were at the PCSK9 locus. Furthermore, nine
of the 16 variants represented the strongest signal at a given locus,
three for a 2nd signal, and four for the 3rd or additional signals.
These functional variants covered a wide allele frequency
spectrum (MAF: 0.003–0.481), including five less common or rare
variants observed only in African Americans.
Discussion
This study evaluated densely spaced SNPs at 58 lipid loci across
three ancestrally diverse populations. The results support evidence
that allelic heterogeneity is a frequent feature of polygenic traits
[5,49] and extend the findings to non-European populations,
especially to African ancestry populations that have high levels of
haplotype diversity. The results also provide strong evidence that
fine mapping at GWAS loci can identify population-specific
signals. Despite comparable sample sizes, we identified more
signals per locus and more signals overall in African Americans (34
signals at 10 loci) compared to Europeans (21 signals at nine loci)
and East Asians (nine signals at four loci), and 15 of the 34 signals
identified in African Americans were population-specific (Table 1,
Table 2, Table 3). These observations may reflect the larger
number of SNPs genotyped in African Americans (Table S2),
variation across populations subject to natural selection during
human evolution [14], or genetic drift [50]. Due to the varied
number of signals per locus, different associated markers, and
different effect sizes, the phenotypic variance explained differs
across populations [51–53]. Sampling variability, epistasis, and
gene-environment interactions may cause over- or under-estima-
tion of the proportion of explained phenotypic variance. In this
study, we also observed that many population-specific signals,
including those at PCSK9 and APOA5, are largely confirmatory
[20,22,54]; however, the association evidence at other signals, in
particular the additional signals at APOE, LDLR, and APOC1
identified by the conditional analyses, requires replication in future
studies.
At PCSK9, the strongest signal C679X identified in African
Americans is population-specific and showed substantially stronger
evidence of association with LDL-C (P = 4.1610222) compared to
the GWAS index SNP rs2479409 [5] (P = 0.12) and the most
strongly associated SNP R46L identified via fine-mapping [7]
(P = 2.361023), both of which were previously reported in
Europeans. The proportion of phenotypic variance explained in
African Americans increased from 0.16% by the GWAS index
SNP to 1.3% by the Metabochip signal C679X, and all variants at
the locus together explained 3.6% of the total variation in LDL-C,
providing evidence that heritability at identified loci may be
underestimated by GWAS [7]. A limitation of these variance
estimates is that calculations included the SNPs based simply on
their significant association P values rather than the variants with
biological function, which could over-estimate effects due to the
winner’s curse.
Results across the genotyped loci demonstrated that the
majority of signals were represented by common variants, yet
high-density genotyping also identified less common and rare
variants associated with lipid traits. At PCSK9, the MAFs of six out
of the seven signals were ,0.05 in African Americans. These
signals, along with other low frequency variants identified at
APOE, LDLR, LCAT, APOB, APOC1, and LPL provide evidence of
the substantial contribution of low frequency genetic variants to
the variance of lipid traits [6]. Other variants, some with very low
allele frequency, may exist at these loci, suggesting that future
sequencing studies may identify additional functional variants that
influence lipid variation.
Sequential conditional analyses provided further insight into the
genetic architecture of the established lipid loci by explaining
additional phenotypic variation and revealing complex patterns of
Figure 2. Trans-ethnic high-density genotyping narrows the
association signal at the HDL-C locus PPP1R3B. Association in
Europeans (A), East Asians (B), African Americans (C) and in a combined
trans-ethnic meta-analysis (D). Index SNP rs6601299 colored in purple is
the variant showing strongest evidence of association in the combined
trans-ethnic meta-analysis.
doi:10.1371/journal.pgen.1003379.g002
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association. We observed loci at which signals were not
independent of each other, but partially correlated based on
moderate LD estimates and changes of association statistics before
and after accounting for other signals. For these dependent signals,
such as those at TOMM4-APOE-APOC4, the significance of
residual association would increase when trait-increasing alleles
were present on opposite haplotypes and decrease when trait-
increasing alleles were on the same haplotype. Other signals that
appeared to be independent on the basis of low pairwise LD and
unchanged association evidence after conditional analysis may still
be partially tagging an un-typed, yet influential, variant [55–57].
Therefore, deeper sequencing that identifies all variants at a locus
will be required to characterize more fully the allelic heterogeneity
and the patterns of association.
One of the major goals of high-density genotyping is to aid in
identification of the functional variants by recognizing the most
compelling candidate variants for experimental study. Because of the
diverse LD structure across populations, particularly in terms of the
limited LD extent in African ancestry populations, trans-ethnic fine-
mapping of GWAS loci can narrow the region where functional
variants are most likely to reside. This study was able to narrow the
association signals at five lipid loci, based on the much smaller subsets
of most strongly associated variants located in smaller regions. One
signal was localized to a reported causal variant (GCKR-P446L) [28]
and another to an uncharacterized nonsynonymous variant (SLC12A4-
E4G near LCAT). These findings demonstrate that trans-ethnic
association analyses can increase the resolution of fine-mapping by
enlarging the haplotypic diversity of samples with different ancestries
and consequently, narrowing the sets of candidate functional variants
[58,59]. The previously described functional variants at LCAT [44] and
ABCA1 [42,43], which are not present on the Metabochip, were
physically located 22 kb and .43 kb away from the narrowed
association signals observed in this study (Table 4).
Refining signals by trans-ethnic meta-analysis largely relies not only
on the existence of distinct LD patterns across ancestry groups but also
on shared functional variants. If functional variants are shared across
populations, as observed with GCKR-P446L, performing trans-ethnic
meta-analysis and integrating LD information across different
populations may refine the signal. On the contrary, if trait variation
is influenced by distinct functional variants across populations, as our
data suggest for APOA5 (Figure S6A–S6D), the lead SNPs produced by
meta-analysis would be influenced by the sample size, magnitude of
genetic effects, and allele frequencies. Similarly, in the case of
population-specific functional variants, such as those at PCSK9, the
results from meta-analysis would reflect the association in one
particular population rather than the combined effect across
populations if signals unique to this population drive the results.
Therefore, accurate assessment of allelic variability is needed on a
population-by-population and locus-by-locus basis.
Although genotype imputation has become a standard practice to
increase genome coverage in GWAS by predicting the genotypes at
SNPs that are not directly genotyped, imputation accuracy tends to be
lower for rare variants owing to the lower degree of LD and the more
challenging haplotype reconstruction [60]. In addition, African
American samples pose a challenge for imputation due to their varying
degree of admixture [61]. A major strength of our study is that all
variants we tested for association were directly genotyped using the
Metabochip, which was designed to provide a high-density coverage
for both overall SNPs and low frequency variants concentrated around
GWAS-identified loci and/or signals [9,10]. This approach increases
the reliability of our association results overall, but in particular the
variants with low allele frequencies.
In conclusion, we performed a large-scale trans-ethnic fine-mapping
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high-density genotyping array and focusing on diverse groups including
African Americans, East Asians, and Europeans. Our results highlight
the value of high-density genotyping in diverse populations to identify a
wider spectrum of susceptibility variants at established loci, both in
terms of additional signals and in terms of population-specific and/or
potentially functional variants. The additional signals revealed through
the sequential conditional analyses lead to a 1.3- to 1.8-fold increase in
the explained phenotypic variance across the different populations. In
addition, integrating diverse LD patterns across diverse ancestry groups
allows for the refinement of association signals. Lastly, our findings that
74% of the reported functional variants exhibited the strongest
association at these densely typed signals suggest that at loci and signals
where functional variants are unknown, the variants with strongest
association may be good candidates for functional assessment.
Materials and Methods
Study populations and phenotypes
The 6,832 African Americans studied are comprised of individuals
from the Atherosclerosis Risk in Communities Study (ARIC) [62], the
Multiethnic Cohort Study (MEC) [63], and the Women’s Health
Initiative (WHI) [64,65] that are part of Population Architecture
using Genomics and Epidemiology (PAGE) consortium [66] and
from Hypertensive Genetic Epidemiology Network (HyperGEN)
[67]. The 9,449 East Asian samples are comprised of 1,716 Filipinos
from the Cebu Longitudinal Health and Nutrition Survey (CLHNS)
[68] and 7,733 Chinese from Taiwan-Metabochip Study for
Cardiovascular Disease (TAICHI). The 10,829 European samples
are comprised of Finnish and Norwegian individuals; the Finns are
from the Finland-United States Investigation of NIDDM Genetics
(FUSION), Dehko 2D 2007 (D2D2007), Diabetes Prevention Study
(DPS), Dose-Responses to Exercise Training (DR’s EXTRA), and
Metabolic Syndrome in Men (METSIM) [69,70], and the Norwe-
gians were from the cohorts of Nord-Trøndelag Health Study
(HUNT 2) and the Tromsø Study (TROMSO) [71,72].
All study protocols were approved by Institutional Review
Boards at their respective sites. Brief descriptions of the studies
are provided in the Text S1. General characteristics and
measurements of TG, HDL-C, and LDL-C in each cohort are
summarized in Table S1. Values of triglycerides were natural log
transformed to approximate normality in each study sample
separately.
Table 5. Reported functional variants exhibited the strongest association at a signal (P,1024).





association at a signal Signal Ethnic group* MAF Notes
PCSK9: rs28362286 (C679X) [22] Yes rs28362286 1st AA 0.009 Same variant
PCSK9: rs28362263 (A443T) [29] Yes rs28362263 2nd AA 0.097 Same variant
PCSK9: rs28362261 (N425S) [30] Yes rs28362261 3rd AA 0.017 Same variant
PCSK9: rs67608943 (Y142X) [22] Yes rs67608943 4th AA 0.004 Same variant
PCSK9: rs72646508 (L253F) [22] Yes rs72646508 5th AA 0.003 Same variant
APOE: rs7412 (R176C) [23] Yes rs7412 1st AA, ASN, EUR 0.056–0.110 Same variant
APOE: rs769455 (R163C) [31] Yes rs769455 2nd AA 0.020 Same variant
APOA5: rs3135506 (S19W) [26] Yes rs3135506 1st AA 0.058 Same variant
APOA5: rs651821(-3A.G) [32] Yes rs651821 1st ASN 0.275 Same variant
APOA5: rs2075291 (G185C) [25] Yes rs2075291 2nd ASN 0.064 Same variant
GCKR: rs1260326 (L446P) [28] Yes rs1260326 1st AA, EUR 0.149–0.350 Same variant
SORT1: rs12740374 [18] Yes rs12740374 1st AA 0.247 Same variant
CETP: rs17231520 [33] Yes rs17231520 3rd AA 0.069 Same variant
LIPC: rs2070895 [34] Proxy: rs1077834 (LD
r2 = 1.00)
rs1077834 1st, 2nd AA, EUR 0.481 LD r2 = 1.00
APOB: rs7575840 [35] Yes rs934198 1st EUR 0.298 LD r2 = 0.98
LPL: rs328 (S447X) [36] Yes rs1803924 1st ASN 0.095 LD r2 = 0.96
LDLR: rs688 (N591N) [37] Yes rs73015011, rs112898275 1st AA, EUR ---- LD r2,0.01
LPL: rs1801177 (D9N) [38] Yes rs75551077, rs15285 1st AA, EUR ---- LD r2,0.02
HMGCR: rs3761740 (-911C.A) [39] Proxy: rs17238330 (LD
r2 = 1.00)
rs12916 1st EUR ---- LD r2,0.20
LDLR: -139C.G [40] No ---- ---- ---- ---- ----
LPL: rs268 (N291S) [41] No ---- ---- ---- ---- ----
ABCA1: rs9282541 (R230C) [42] No ---- ---- ---- ---- ----
ABCA1: rs2066715 (V825I) [43] No ---- ---- ---- ---- ----
LCAT: rs28940887(R159W) [44] No ---- ---- ---- ---- ----
PLTP: R235W [45] No ---- ---- ---- ---- ----
LIPG: rs77960347 (A396S) [46] No ---- ---- ---- ---- ----
LIPG: rs34474737 [47] No ---- ---- ---- ---- ----
*AA, African American; EUR, European; ASN, East Asian.
doi:10.1371/journal.pgen.1003379.t005
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Genotyping
We genotyped all study samples with the Metabochip according
to the manufacturer’s protocol (Illumina, San Diego, CA, USA).
Table S1 summarizes the quality control criteria of genotyping,
including call rate, sample success rate, Hardy-Weinberg equilib-
rium, and MAF that varied across studies.
Statistical analyses
We applied multiple linear regression models and assumed an
additive mode of inheritance to test for association between
genotypes and HDL-C, LDL-C, or log-transformed triglycerides.
We performed each test of association separately in each of the 11
groups (Table S1) prior to meta-analysis. We constructed principal
components (PCs) using the software EIGENSOFT. We used age
and sex as covariates in each individual cohort; other cohort-
specific covariates including age2, enrollment site, socioeconomic
status, and principal components varied across studies (Table S1).
The European samples include type 2 diabetes (T2D) cases and
unaffected controls; to avoid confounding due to T2D status,
samples were analyzed separately as Finnish T2D patients, Finnish
unaffected individuals, Norwegian T2D patients, and Norwegian
unaffected individuals.
We first conducted the meta-analysis within the African Americans,
East Asians, and Europeans separately. We then performed combined
trans-ethnic meta-analyses by combining the statistics of each the 11
participating groups to assess the association with the SNPs at the 58
lipids loci.
At loci that exhibited evidence of association at P,1024, we next
performed a series of sequential conditional analyses by adding the
most strongly associated SNP into the regression model as a
covariate and testing all remaining regional SNPs for association.
We conducted a set of sequential conditional analyses until the
strongest SNP showed a conditional P value.1024 and had no
annotation or literature evidence that suggested a functional role.
For single SNP analyses, we applied PLINK (http://pngu.mgh.
harvard.edu/,purcell/plink/) [73] for population-based studies.
We used the R package GWAF [74] for the family-based study of
HyperGEN. We applied an inverse variance-weighted fixed-effect
meta-analysis implemented in METAL [75].
Unless otherwise noted, linkage disequilibrium estimates were
obtained from the 1000 Genomes Project November 2010 release.
SNP positions correspond to hg18.
We performed haplotype analysis at LDL-C locus TOMM40-
APOE-APOC4 in 5,593 unrelated African Americans from the
PAGE consortium, using the ‘haplo.stat’ R package. Haplotypes
and haplotype frequencies were estimated using the R function
‘haplo.em’. The association between haplotypes and LDL-C was
assessed using the R function ‘haplo.glm’. An additive model was
assumed, in which the regression coefficient b represents the
expected change in LDL-C level with each additional copy of the
specific haplotype compared with the reference haplotype, which
was set as the A-A (trait increasing-increasing) haplotype.
We created the regional association plots using LocusZoom
[76]. To plot the association results in Europeans and East Asians,
we used the LocusZoom-implemented LD estimates from the 1000
Genomes Project (June 2010) CEU and CHB+JPT samples, whose
LD structures are similar to our samples with European and East
Asian ancestries. We applied the user-supplied LD calculated from
the genotype data of the PAGE African American samples to plot
the regional association in African Americans [9], because the LD
patterns may vary from any pre-computed LD sources imple-
mented in LocusZoom.
We evaluated the proportion of variance explained by a single
SNP or any given locus by including the SNP or a set of SNPs into
a linear regression model with all covariates used in association
analysis and calculating the R2 for the full model. We subtracted
the variance explained by a basic model in which only covariates
were included from the variance we obtained from the full model.
We performed these analyses using SAS version 9.2 (SAS Institute,
Cary, NC, USA).
Supporting Information
Figure S1 LDL-C locus TOMM40-APOE-APOC4 exhibited
seven signals in African Americans. Each SNP was colored
according to its LD (r2) in PAGE consortium with the strongest
SNP rs7412 (R176C) colored in purple.
(PDF)
Figure S2 Association at TG locus GCKR in Europeans (A), East
Asians (B), African Americans (C), and trans-ethnic meta-analysis
(D). Index SNP rs1260326 (P446L) is the variant showing the
strongest evidence of association in trans-ethnic meta-analysis.
(PDF)
Figure S3 Association at LDL-C locus ABO in Europeans (A),
East Asians (B), African Americans (C), and trans-ethnic meta-
analysis (D). Index SNP rs2519093 is the variant showing the
strongest evidence of association in trans-ethnic meta-analysis.
(PDF)
Figure S4 Association at HDL-C locus LCAT in Europeans (A),
East Asians (B), African Americans (C), and trans-ethnic meta-
analysis (D). Index SNP rs3785100 (SLC12A4-E4G) is the variant
showing the strongest evidence of association in trans-ethnic meta-
analysis.
(PDF)
Figure S5 Association at HDL-C locus ABCA1 in Europeans (A),
East Asians (B), African Americans (C), and trans-ethnic meta-
analysis (D). Index SNP rs1883025 is the variant showing the
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